Norelgestromin and Ethinyl Estradiol Transdermal System contains combination hormone medication and is used to prevent pregnancy.

This is the third hormonal transdermal patch to be approved from Zydus' generics portfolio. The transdermal patch will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad.

Norelgestromin and Ethinyl Estradiol Transdermal System had annual sales of $330 million in the United States (IQVIA MAT July 2023).

The group now has 380 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company had reported 109.7% surge in net profit to Rs 1,086.9 crore in Q1 FY24 as compared with Rs 518.3 crore posted in Q1 FY23. Revenue from operations jumped 29.6% to Rs 5,139.6 crore during the quarter as compared with Rs 3,964.4 crore recorded in same quarter last year.

The scrip added 0.46% to currently trade at Rs 642.65 on the BSE.